Patrizia D'amelio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4534535/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	From the Bench to the Bedside: Branched Amino Acid and Micronutrient Strategies to Improve Mitochondrial Dysfunction Leading to Sarcopenia. Nutrients, 2022, 14, 483.	1.7	13
2	Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study. Nutrients, 2022, 14, 2683.	1.7	6
3	Vitamin D Deficiency and Risk of Metabolic Syndrome in Aging Men. World Journal of Men?s Health, 2021, 39, 291.	1.7	8
4	The doll therapy as a first line treatment for behavioral and psychologic symptoms of dementia in nursing homes residents: a randomized, controlled study. BMC Geriatrics, 2021, 21, 545.	1.1	7
5	From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study. Clinical Nutrition, 2020, 39, 2080-2091.	2.3	49
6	Circulating Long Non-Coding RNA GAS5 Is Overexpressed in Serum from Osteoporotic Patients and Is Associated with Increased Risk of Bone Fragility. International Journal of Molecular Sciences, 2020, 21, 6930.	1.8	12
7	Editorial: Updates on Osteoimmunology: What's New on the Crosstalk Between Bone and Immune Cells. Frontiers in Endocrinology, 2020, 11, 74.	1.5	4
8	The scent of emotions: A systematic review of human intra―and interspecific chemical communication of emotions. Brain and Behavior, 2020, 10, e01585.	1.0	31
9	Hypovitaminosis D and Aging: Is There a Role in Muscle and Brain Health?. Nutrients, 2020, 12, 628.	1.7	19
10	Hyponatremia, Hypokalemia, and Fragility Fractures in Old Patients: More than an Association?. Calcified Tissue International, 2020, 106, 599-607.	1.5	10
11	What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss?. Frontiers in Immunology, 2019, 10, 505.	2.2	51
12	Gut Microbiota, Immune System, and Bone. Calcified Tissue International, 2018, 102, 415-425.	1.5	160
13	Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. Annals of the Rheumatic Diseases, 2018, 77, 378-385.	0.5	21
14	Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent <scp>PTH</scp> â€induced bone anabolism in mice. EMBO Reports, 2018, 19, 156-171.	2.0	45
15	Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients, 2018, 10, 1656.	1.7	478
16	Type 2 diabetes affects bone cells precursors and bone turnover. BMC Endocrine Disorders, 2018, 18, 55.	0.9	42
17	Editorial: Bone: Endocrine Target and Organ. Frontiers in Endocrinology, 2017, 8, 354.	1.5	6
18	Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study. PLoS ONE, 2017, 12, e0178463.	1.1	43

#	Article	IF	CITATIONS
19	ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo. Journal of Immunology, 2016, 197, 3905-3916.	0.4	34
20	Osteoimmunology: from mice to humans. BoneKEy Reports, 2016, 5, 802.	2.7	29
21	Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves. PLoS ONE, 2016, 11, e0168553.	1.1	10
22	C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget, 2016, 7, 45525-45537.	0.8	24
23	Inappropriate Proton Pump Inhibitor Prescription in Elderly Adults: As Usual AsÂDangerous. Journal of the American Geriatrics Society, 2015, 63, 2198-2199.	1.3	6
24	Bone-Immune Cell Crosstalk: Bone Diseases. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	60
25	Pathogenesis of Bone Diseases: The Role of Immune System. Journal of Immunology Research, 2015, 2015, 1-2.	0.9	4
26	Male Osteoporosis in the Elderly. International Journal of Endocrinology, 2015, 2015, 1-8.	0.6	28
27	Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporosis International, 2015, 26, 1629-1638.	1.3	33
28	Effect of intermittent PTH treatment on plasma glucose in osteoporosis: A randomized trial. Bone, 2015, 76, 177-184.	1.4	18
29	Hypovitaminosis D and Organ Damage In Patients With Arterial Hypertension: A Multicenter Double Blind Randomised Controlled Trial of Cholecalciferol Supplementation (HYPODD). High Blood Pressure and Cardiovascular Prevention, 2015, 22, 135-142.	1.0	4
30	Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients. Osteoporosis International, 2015, 26, 2785-2791.	1.3	26
31	IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice. Cell Metabolism, 2015, 22, 799-810.	7.2	82
32	DKK-1 in prostate cancer diagnosis and follow up. BMC Clinical Pathology, 2014, 14, 11.	1.8	5
33	Prevalence of Postmenopausal Osteoporosis in Italy and Validation of Decision Rules for Referring Women for Bone Densitometry. Calcified Tissue International, 2013, 92, 437-443.	1.5	13
34	Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. British Journal of Cancer, 2013, 108, 2525-2536.	2.9	31
35	The use of raloxifene in osteoporosis treatment . Expert Opinion on Pharmacotherapy, 2013, 14, 949-956.	0.9	51
36	The immune system and postmenopausal osteoporosis. Immunological Investigations, 2013, 42, 544-554.	1.0	19

#	Article	IF	CITATIONS
37	Bone metastases in gastric cancer follow a RANKL-independent mechanism. Oncology Reports, 2013, 29, 1453-1458.	1.2	13
38	The Interplay between the Bone and the Immune System. Clinical and Developmental Immunology, 2013, 2013, 1-16.	3.3	153
39	The Crosstalk between the Bone and the Immune System: Osteoimmunology. Clinical and Developmental Immunology, 2013, 2013, 1-2.	3.3	25
40	Teriparatide increases the maturation of circulating osteoblast precursors. Osteoporosis International, 2012, 23, 1245-1253.	1.3	29
41	Impact of a Phone Follow-Up Program on Persistence with Teriparatide or PTH(1–84) Treatment. Calcified Tissue International, 2012, 90, 272-278.	1.5	8
42	Energy metabolism and the skeleton: Reciprocal interplay. World Journal of Orthopedics, 2012, 3, 190.	0.8	14
43	Clinical characteristics and incidence of first fracture in a consecutive sample of post-menopausal women attending osteoporosis centers: The PROTEO-1 study. Journal of Endocrinological Investigation, 2011, 34, 534-540.	1.8	2
44	Multinucleated giant cells with an osteoclast phenotype derived from caprine peripheral blood mononuclear cells. Veterinary Journal, 2011, 189, 361-363.	0.6	3
45	Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporosis International, 2011, 22, 2869-2877.	1.3	40
46	Microdamage Accumulation Changes According to Animal Mass: An Intraspecies Investigation. Calcified Tissue International, 2011, 88, 409-415.	1.5	6
47	Interactions between the immune system and bone. World Journal of Orthopedics, 2011, 2, 25.	0.8	10
48	Cytokines and Bone. , 2011, , 385-401.		0
49	The Role of Circulating Bone Cell Precursors in Fracture Healing. Calcified Tissue International, 2010, 86, 463-469.	1.5	34
50	Alendronate reduces osteoclast precursors in osteoporosis. Osteoporosis International, 2010, 21, 1741-1750.	1.3	42
51	Osteoclastogenesis in peripheral blood mononuclear cell cultures of periprosthetic osteolysis patients and the phenotype of T cells localized in periprosthetic tissues. Biomaterials, 2010, 31, 7519-7525.	5.7	27
52	lloprost modulates the immune response in systemic sclerosis. BMC Immunology, 2010, 11, 62.	0.9	16
53	Analysis of vitamin D receptor expression and clinical correlations in patients with ovarian cancer. Gynecologic Oncology, 2010, 119, 121-124.	0.6	26
54	Iron metabolism markers and haptoglobin phenotypes in susceptibility to HSVâ€1 or/and HSVâ€2 lesion relapses. Cell Biochemistry and Function, 2010, 28, 142-148.	1.4	4

#	Article	IF	CITATIONS
55	Immune System and Postmenopausal Bone Loss. Clinical Reviews in Bone and Mineral Metabolism, 2009, 7, 262-268.	1.3	5
56	Risedronate Reduces Osteoclast Precursors and Cytokine Production in Postmenopausal Osteoporotic Women. Journal of Bone and Mineral Research, 2008, 23, 373-379.	3.1	51
57	Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis. Bone, 2008, 43, 92-100.	1.4	292
58	Role of iron metabolism and oxidative damage in postmenopausal bone loss. Bone, 2008, 43, 1010-1015.	1.4	57
59	Bone Mineral Density and Singh Index Predict Bone Mechanical Properties of Human Femur. Connective Tissue Research, 2008, 49, 99-104.	1.1	36
60	Dedicated Image Analysis Software Tool for the Evaluation of the Resorption Activity of Cultured Osteoclasts. Journal of Imaging Science and Technology, 2008, 52, 30508-1-30508-9.	0.3	5
61	Osteoclasts Are Active in Bone Forming Metastases of Prostate Cancer Patients. PLoS ONE, 2008, 3, e3627.	1.1	77
62	Allometric scaling and biomechanical behavior of the bone tissue: An experimental intraspecific investigation. Bone, 2007, 40, 1635-1642.	1.4	29
63	Preoperative localization of parathyroid adenoma with sonography and 99mTc-sestamibi scintigraphy in primary hyperparathyroidism. Journal of Clinical Ultrasound, 2007, 35, 186-190.	0.4	29
64	Hypovitaminosis D in Internal Medicine Inpatients. Calcified Tissue International, 2007, 80, 76-80.	1.5	17
65	Health-related quality of life in severe osteoporosis. Aging Clinical and Experimental Research, 2007, 19, 28-30.	1.4	3
66	Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans?. Bone, 2006, 39, 658-665.	1.4	20
67	Cross-sectional geometrical properties of distal radius and ulna in large, medium and toy breed dogs. Journal of Biomechanics, 2006, 39, 302-311.	0.9	34
68	Effects of Lifestyle and Risk Factors on Bone Mineral Density in a Cohort of Italian Women: Suggestion for a New Decision Rule. Calcified Tissue International, 2005, 77, 72-78.	1.5	18
69	Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB Journal, 2005, 19, 1-16.	0.2	63
70	Effects of Potassium Citrate Supplementation on Bone Metabolism. Calcified Tissue International, 2004, 74, 330-335.	1.5	98
71	Densitometric Study of Human Developing Dry Bones. Journal of Clinical Densitometry, 2002, 5, 73-78.	0.5	1
72	Densitometric Study of Dry Human Mandible. Journal of Clinical Densitometry, 2002, 5, 363-367.	0.5	11

#	Article	IF	CITATIONS
73	High density lipoproteins (HDL) in women with postmenopausal osteoporosis: a preliminary study. Menopause, 2001, 8, 429-432.	0.8	31
74	Ossification Centers of Human Femur. Calcified Tissue International, 2000, 66, 255-258.	1.5	11
75	Densitometric Study of Developing Femur. Calcified Tissue International, 1999, 64, 133-136.	1.5	10
76	Role of estrogen replacement therapy in the control of immune system in postmenopausal osteoporosis. Bone Abstracts, 0, , .	0.0	0
77	Bone pain, muscle weakness and gait abnormalities in a 57-year-old woman: tumor induced osteomalacia. Research, 0, 1, .	0.0	0